Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children’s Hospital of Fudan University

Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children’s Hospital of Fudan University

Abstract Background The humanized anti-disialoganglioside-2 monoclonal antibody naxitamab was approved in the USA in 2020 for the treatment of patients with relapsed/refractory high-risk neuroblastoma, limited to the bone or bone marrow, in combination with granulocyte-macrophage colony-stimulating...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaowen Qian, Dufei Zhang, Kai Li, Weiming Chen, Peijun Zhuang, Hongsheng Wang, Zhixian Lei, Yan Li, James Eldridge, Kuiran Dong, Xiaowen Zhai
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-12-01
Series:Drugs - Real World Outcomes
Online Access:https://doi.org/10.1007/s40801-024-00468-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40801-024-00468-5

Similar Items